| Micro-channel |
 |
|
|
|
|
|
| |
| The seven treatment areas will become the pharmaceutical giants' main source of revenue! |
| |
| Author：中國銘鉉 企劃部 Release Time：2017-9-27 11:26:04 Number Browse：2237 |
| |
According to a new report from QuintilesIMS, a multimedia subsidiary of the world's leading drug information research institute, the global drug spending will reach $1.4 trillion by 2020. This is an astonishing number.
Of the $1.4 trillion, about 40 percent came from seven important areas of treatment, much of it earned by big drug makers, the report said.
1 cancer
Projected sales for 2020: $100 billion ~ $120 billion
Cancer remains the most profitable treatment for drug giants until 2020. The company expects sales of cancer drugs to be between $100 billion and $120 billion in three years. Annual growth is expected to be 9% to 12%.
Currently, roche, a Swiss drugmaker, is the leader of the tumor market. , however, the new base (its) Revlimid (Lenalidomide capsules, drug Lenalidomide capsule/complex beauty) is expected within the next few years will continue to be the highest sales cancer drugs (the U.S. market in 2016 sales of $4.417 billion, $3.535 billion in 2015, up 25%; In the first quarter of 2017, $12.34 billion, up 24% from a year earlier. And several drugs giants will also get billions of dollars from oncology products, including abbvie, bristol-myers squibb and gilead sciences, novartis, Pfizer, have important anticancer drug products.
2 diabetes
Projected sales for 2020: $107 billion to $113 billion
It is not expected that the cost of diabetes drugs will be close to the top of the range of treatments, with global sales likely to reach $107 billion to $113 billion by 2020. According to the world health organization, the number of diabetics in the world reached 422 million three years ago, and the number may be even more alarming.
For now, novo and nord have the largest share of the diabetes market, with sales of more than $12.9 billion last year. In the next few years, the Danish pharmaceutical companies still seem to be able to maintain the top position, its diabetes drug including Victoza (Liraglutide Injection, lalu peptide Injection/labored and power), Tresiba (Insulin Degludec Injection, DE valley Insulin Injection) and the research and development of Semaglutide (cable distribution of peptide). In addition to controlling blood sugar, Semaglutide also reduces weight loss, and novo nord has high hopes for it.
3 the pain
Projected sales for 2020: $82 billion to $85 billion
By 2020, painkillers are expected to be the third-largest source of revenue for big pharma, with sales of $82 billion to $85 billion. Such drugs include musculoskeletal pain, arthritis, anaesthesia, painkillers (anaesthetic and non-anesthetic) and migraines.
Anjin is the main representative of large biotechnology companies in the field of pain therapy. The company is working with novartis to develop an experimental migraine drug Erenumab, which could peak sales of more than $2 billion if approved.
4 cardiovascular disease
Projected sales: $73 billion to $76 billion by 2020
The company estimates that the sales of cardiovascular drugs will reach $73 billion to $76 billion by 2020. About a third of that may come from the emerging world drug market. Cardiovascular drugs include high blood pressure, heart disease and cholesterol.
J&j's Xarelto (Rivaroxaban tablet, Levi's) is currently the world's No.1 market for cardiovascular drugs, with sales of nearly $5 billion last year. However, bristol-myers squibb and Pfizer's anticoagulant Eliquis (Apixaban Tablets/aleca) could surpass Xarelto's lead in a few years. This year, however, on August 26, the European society of cardiology conference in Barcelona, according to the information from the patients with severe atherosclerosis Xarelto proved to be able to make the potentially fatal stroke and a 24% lower risk of heart attack, so as to improve its sales prospects. The two are better than the other.
5 autoimmune disease
Projected sales for 2020: $55 billion to $65 billion
By 2020, its own immune-disease drugs could give big pharmaceutical companies $55 billion to $65 billion in sales, according to quintiles. The treatment category is also expected to be one of the fastest-growing areas, with a compound annual growth rate of 11 to 14 percent.
Several big drugmakers compete with each other in the market for autoimmune diseases. Alberi said its current sales of the best drug, Humira (Adalimumab Solution for Injection, Adalimumab Injection/merlot) sold more than $16 billion in sales last year. Meanwhile, Celgene's Apremilast tablet, which is expected to be the world's 32nd largest by sales in 2022, is expected to make $2.6 billion in sales in 2022.
Respiratory diseases
Projected sales for 2020: $53 billion to $56 billion
The respiratory disease treatment is expected to reach $530 to $56 billion by 2020. The most common respiratory diseases include asthma, allergies and chronic obstructive pulmonary disease (COPD).
Despite the size of the global market for respiratory diseases, the number of blockbuster drugs to treat these indications is relatively small. According to market research firm EvaluatePharma reported that there are only a kind of respiratory disease drugs will be among the sales plunged in the current within five years, namely the boehringer ingelheim corporation Spiriva (Tiotropium Bromide Powder for Inhalation, thiamethoxam Bromide Powder inhaler/SiLi China). The asthma and COPD drugs are expected to be $2.7 billion in sales in 2020, down from current sales levels.
7 viral hepatitis
Projected sales for 2020: $45 billion to $55 billion
Kuntai expects sales of drugs to treat viral hepatitis in 2020 at $45 billion to $55 billion, with compound annual growth of 7% to 10%. The world health organization estimates that some 257 million people suffer from chronic hepatitis b virus (HBV) infection and 71 million are infected with chronic hepatitis c virus (HCV).
Although HBV infects more patients, HCV treatment market is creating the most benefits for large pharmaceutical companies. The current leader in HCV therapy is gilead sciences. In 2016, the big biotech company received $14.8 billion from its HCV drugs. However, gilead's HCV treatment drug revenue is declining. The company has found that the number of such patients has declined, particularly in the United States, largely because the most serious patients have been cured. In addition, increased competition from other drugmakers has led to lower prices for HCV drugs.
|
| |
Previous article：Technical standards for quality and efficacy of generic drugs (interim)
Next article：The third batch of standards officially released the standard coverage of implants
|
| |
|
|
